Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.

MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...

BI-765049 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

BARS-13 is under clinical development by Beijing Advaccine Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.

AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition ...

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Hodgkin Lymphoma.

NUC-7738 is under clinical development by NuCana and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 36% phase ...